Search

everythinglearnresearchcommunity

for

Search:↓

A user expressed concern about using low-dose topical finasteride while conceiving, but was reassured that the risk of affecting a fetus is negligible. The user stopped using finasteride during pregnancy and switched to minoxidil and ketoconazole, while others shared experiences and advice on using these treatments safely.

The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

The user experienced decreased libido with saw palmetto and is now considering topical anti-androgens like RU58841, pyrilutamide, and topical dutasteride for hair loss. Minoxidil is also mentioned as a potential addition, but the user is cautious about side effects and availability of treatments.

The conversation is about using alfatradiol (17α-estradiol) as a hair loss treatment. The user is considering adding it to their regimen due to its safety and availability.

A 21-year-old experienced hormone changes after using self-made topical finasteride for hair loss, including a 20% decrease in DHT, a 47% increase in testosterone, and a 39% increase in estradiol. The user previously used minoxidil and microneedling but is now seeking ways to balance hormones, possibly through supplements or dosage adjustments.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

A 29-year-old woman with genetic hair loss started using 0.5 dutasteride a week ago and has noticed increased shedding, no sexual side effects, and less oily skin. She plans to provide updates and is not concerned about potential birth defects as she doesn't plan to have more children.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.

Topical dutasteride is suggested as a low side-effect treatment for hair loss, with a proposed dose of 0.025% 1ml/day. It is considered better than finasteride due to its even inhibition of DHT isoforms and lower systemic absorption.

A 22-year-old is experiencing hair loss after transitioning from fem HRT to DIY testosterone therapy and is considering using Dutasteride while also taking Saw Palmetto. They are concerned about the impact on virilization and proper development.

The conversation is about using topical finasteride or dutasteride with a testosterone and NPP cycle for hair loss. The planned treatment includes microneedling, minoxidil, pyrilutamide, and dutasteride applied topically.

The user convinced their trichologist to prescribe topical finasteride after using topical estradiol and progesterone for hair maintenance. They also discussed the potential impact of "nofap" on hair loss, noting that abstaining for about four months seemed to reduce shedding.

A 30-year-old man experienced significant hair regrowth and improved libido after using finasteride and dutasteride for androgenetic alopecia, with no adverse effects. He plans to reduce dutasteride dosage when trying to conceive and has been using topical minoxidil since 2015.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

The user has not seen results from various hair loss treatments including finasteride, dutasteride, minoxidil, and others over several years and is considering adding RU58841 and starting hormone replacement therapy. They are also experiencing anxiety and contemplating moving to a more accepting environment for their nonbinary identity.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

The conversation discusses the effectiveness of anti-androgens for hair loss, with a preference for topical treatments like RU58841 over oral options due to better scalp concentration and fewer side effects. Topical finasteride at 0.1% may provide some results, especially when combined with a topical androgen receptor antagonist like RU58841.

User added RU and pyrilutamide for hair growth and noticed more baby hairs. Others suggest sticking with fin and min, while some discuss the user's self-image and hair loss severity.

Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.

Visible hair improvement after 10 weeks using minoxidil, estradiol enanthate, acetophenide algestone, and bicalutamide. The user is a 25-year-old male with reduced testosterone levels, expressing a preference for less masculinity.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

A user's regimen to help with their diffuse thinning, which includes taking Pyrilutamide BID, 1mg finasteride daily, 2.5mg oral minoxidil daily, topical minoxidil since August 2021, LLLT every two days, topical fin, progesterone, melatonin, minoxidil (started one week ago), pumpkin seed oil and not dermarolling; other commenters suggested Nizoral for dandruff control and caution when using pre-mixed products with Pyrilutamide.

User experienced feminizing side effects from finasteride and tried RU, alfatradiol, and finasteride without success. They are now considering treatments like Stemoxydine, Zix, Minoxidil, Dermarolling, Eucapil, and a hair transplant.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.

The post discusses a user's successful hair regrowth using finasteride, dutasteride, topical minoxidil, and estrogen over nine months. The user, who is male-to-female (mtf), reports significant regrowth and no side effects beyond typical hormone replacement therapy effects.

The user experienced significant hair regrowth using topical finasteride/minoxidil and oral minoxidil/dutasteride, with some mild side effects that diminished over time. They plan to add microneedling to their regimen and have seen hair shedding cycles every six months, followed by thicker regrowth.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.